- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 101,12 | +0,02 % | Dividendenbekanntmachungen (15.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2969 EUR AMERICAN HOMES 4 RENT US02665T3068 0,3 USD 0,2555 EUR ARES CAPITAL... ► Artikel lesen | |
| ZOETIS | 105,90 | +0,93 % | Zoetis prices $1.75 billion convertible senior notes | ||
| INCYTE | 81,88 | -0,87 % | INCYTE CORPORATION stürzt ab - ich rieche Panik! | ||
| CASSAVA SCIENCES | 2,428 | -2,84 % | Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update | Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced... ► Artikel lesen | |
| AMARIN | 11,800 | -0,84 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 161,00 | +0,62 % | Benchmark bestätigt Kaufempfehlung für Ligand Pharma mit Kursziel von 220 US-Dollar | ||
| ACHIEVE LIFE SCIENCES | 3,700 | -1,07 % | Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program | One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 467,10 | -1,14 % | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| ENZON PHARMACEUTICALS | 0,036 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| TALPHERA | 1,020 | -0,58 % | Talphera, Inc.: Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc.
Cash and investments at September 30, 2025 were $21.3 million; combined... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 36,200 | +1,12 % | RIGEL PHARMACEUTICALS INC - 8-K, Current Report | ||
| ANI PHARMACEUTICALS | 68,50 | -1,44 % | ANI Pharmaceuticals Director Sold $146K In Company Stock | ||
| SAVARA | 5,550 | +0,91 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 6,430 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP | December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical... ► Artikel lesen | |
| ARTIVION | 38,850 | -0,64 % | Artivion, Inc.: Artivion Reports Third Quarter 2025 Financial Results | Third Quarter Highlights:
Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of... ► Artikel lesen |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.